InflaRx Receives the US FDA’s EUA for Gohibic (vilobelimab) to Treat COVID-19
Shots:
- The EUA was based on the P-III trial (PANAMO) evaluating vilobelimab vs PBO in a ratio (1:1) in 369 patients when the drug is administered within 48 hrs. of the patient receiving either IMV or ECMO. The recommended dosage of Gohibic is 800mg, IV after dilution, given ~6 times over the treatment period
- The results showed a reduction in 28-day all-cause mortality of 23.9% over PBO in critically ill invasively mechanically ventilated COVID-19 patients. The results were published in the Lancet Respiratory Medicine
- InflaRx is continuing discussions with the US FDA related to the submission of an application for full approval of Gohibic. The company continues to advance vilobelimab in other indications, incl. pyoderma gangrenosum
Ref: inflarx | Image: inflarx
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
